Artemis Hospitals
Hodgkin's lymphoma treatment cost in India runs from AUD $867 to AUD $3,178 for chemotherapy, while a consultation with a hematologist costs between AUD $58 and AUD $144. Total expenses depend on the cancer stage and cycle frequency. Patients typically save 70–90% compared to Australia and the UK. Top medical hubs include Gurgaon, Delhi, and Bengaluru.
Typical Hodgkin's Lymphoma Treatment Costs in India
Bookimed Expert Insight: Patients requiring precise radiation benefit from Dr. Rela Institute & Medical Centre. They use linear accelerators with 1 mm accuracy. For complex cases, HCG Manavata Cancer Centre offers integrated care with over 40 consultant oncologists on staff. Advanced diagnostic needs are met at centres like Artemis Hospitals. It was the first JCI-accredited facility in South Asia.
| India | Thailand | Turkey | |
| Radiation therapy for colorectal cancer | from AUD $4,623 | from AUD $7,946 | from AUD $10,113 |
| Chemotherapy for breast cancer | from AUD $5,056 | from AUD $4,334 | from AUD $1,734 |
| Chemotherapy | from AUD $795 | from AUD $2,889 | from AUD $3,511 |
| Biological therapy | from AUD $2,600 | from AUD $7,223 | from AUD $7,946 |
| Immunotherapy with Keytruda (Pembolizumab) | from AUD $5,056 | from AUD $11,557 | from AUD $4,767 |
No hidden fees – just official clinic prices. Pay at the clinic for Hodgkin's lymphoma treatment and use a flexible instalment plan if needed.
Bookimed is committed to your safety. We only work with medical institutions that maintain high international standards in Hodgkin's lymphoma treatment and have the necessary licenses to serve international patients worldwide.
Bookimed offers free expert assistance. A personal medical coordinator supports you before, during, and after your treatment, solving any issues. You're never alone on your Hodgkin's lymphoma treatment journey.
Dr Girish Badarkhe is a clinical haematologist at HCG Manavata Cancer Centre who has managed over 1,000 cases involving bone marrow and blood disorders.
Professor Mallikarjun Kalashetty is a dedicated oncohaematologist at Manipal Hospital specialising in bone marrow transplantation and lymphatic cancers.
Professor Deenadayalan Munirathnam is a senior specialist in paediatric haematology and oncology at Global Hospital Mumbai. He focuses on blood disorders in children and young adults.
Indian oncology centres report a 5-year survival rate of 83.6% for Hodgkin lymphoma. This reflects high standards in haematology. Standard chemotherapy regimens achieve a 93.5% overall response rate. Early-stage cases yield complete response rates over 92% at JCI-accredited facilities in Delhi, Mumbai, and Bengaluru.
Bookimed Expert Insight: India excels in treating refractory cases through mid-range centres like HCG Manavata. This centre manages 75,000+ patients annually. These institutions provide CAR T-cell therapy and haploidentical stem cell transplants. Such complex interventions often cost 2 to 5 times less than in Western Europe or Australia.
Patient Consensus: Patients find India treats Hodgkin lymphoma with high cure rates up to 95%. Remission is typical within 5 years. Waiting periods of 1 to 2 months may occur at major hospitals. Younger patients below 30 years report particularly favourable recovery prospects during chemotherapy sessions.
Indian oncologists treating Hodgkin lymphoma hold international qualifications. Most senior specialists have completed fellowships at institutions like MD Anderson or Royal Marsden. They often hold European Society for Medical Oncology (ESMO) board certifications. Major centres follow global NCCN and ESMO clinical guidelines.
Bookimed Expert Insight: Indian cancer centres like HCG Manavata Cancer Centre maintain a US-FDA audited research wing. This level of regulatory oversight proves their clinical data and treatment protocols meet strict international benchmarks. High-volume specialists here often manage more lymphoma cases in a single year. This is more than many Western doctors see in five.
Patient Consensus: Patients note that Indian oncologists are highly trusted globally. Many travel from the Middle East to India. They seek the expertise in ABVD and AAVD chemotherapy protocols.
India uses chemotherapy, radiotherapy, and immunotherapy to treat Hodgkin lymphoma. Specialist centres like HCG Manavata Cancer Centre offer specialised technical approaches. These include CAR T-cell therapy and allogeneic bone marrow transplantation. They treat complex or relapsed cases. Treatment protocols typically follow international medical standards.
Bookimed Expert Insight: Indian oncology centres increasingly integrate PET-CT and IBM Watson for Oncology. This helps them reach 96% diagnostic accuracy. Major networks like Manipal Hospitals serve over 2,000,000 international patients annually. This massive volume allows specialists to manage complex cases that smaller regional clinics rarely see.
Patient Consensus: Patients note that Hodgkin lymphoma is highly curable in India. Success rates reach 87–90% even in advanced stages. Patients receiving care in Mumbai or Delhi commonly seek second opinions for relapsed cases.
Indian hospitals offer comprehensive support including dedicated international patient desks, medical visa assistance, and free airport transfers. Specialists like Dr Deenadayalan Munirathnam and Dr Girish Badarkhe provide specialised care. Facilities such as Aster CMI and Manipal Hospitals cater to more than 2,000,000 patients annually with tailored logistics.
Bookimed Expert Insight: Major networks like Apollo and Manipal handle millions of international patients annually. This sets a standard where personal coordinators are included. Patients should look for JCI-accredited centres like Artemis or Apollo. These align with Australian healthcare quality benchmarks and provide smoother post-surgical follow-up.
Patient Consensus: International patients note that clinical care for lymphoma in India is swift. However, proactive logistical planning for housing and financial crowdfunding is often necessary. Detailed peer support groups and social workers are common in high-volume regional hubs.